JANUX THERAPEUTICS INC (JANX) Stock Price & Overview
NASDAQ:JANX • US47103J1051
The current stock price of JANX is 13.84 USD. Today JANX is down by -0.93%. In the past month the price increased by 13.63%. In the past year, price decreased by -54.83%.
JANX Key Statistics
- Market Cap
- 841.887M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.83
- Dividend Yield
- N/A
JANX Stock Performance
JANX Stock Chart
JANX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to JANX. When comparing the yearly performance of all stocks, JANX is a bad performer in the overall market: 90.75% of all stocks are doing better.
JANX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JANX. No worries on liquidiy or solvency for JANX as it has an excellent financial health rating, but there are worries on the profitability.
JANX Earnings
JANX Forecast & Estimates
26 analysts have analysed JANX and the average price target is 61.97 USD. This implies a price increase of 347.72% is expected in the next year compared to the current price of 13.84.
For the next year, analysts expect an EPS growth of -50.24% and a revenue growth -86.02% for JANX
JANX Groups
Sector & Classification
JANX Financial Highlights
Over the last trailing twelve months JANX reported a non-GAAP Earnings per Share(EPS) of -1.83. The EPS decreased by -42.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.34% | ||
| ROE | -11.88% | ||
| Debt/Equity | 0 |
JANX Ownership
JANX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.51 | 406.874B | ||
| AMGN | AMGEN INC | 16.19 | 199.203B | ||
| GILD | GILEAD SCIENCES INC | 16.28 | 178.678B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.56 | 116.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.25 | 80.332B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.98 | 42.526B | ||
| INSM | INSMED INC | N/A | 30.205B | ||
| NTRA | NATERA INC | N/A | 28.081B | ||
| BIIB | BIOGEN INC | 11.5 | 27.132B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 20.958B | ||
| MRNA | MODERNA INC | N/A | 20.742B | ||
| EXAS | EXACT SCIENCES CORP | 340.51 | 19.757B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.5B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About JANX
Company Profile
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 109 full-time employees. The company went IPO on 2021-06-11. The company has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Company Info
JANUX THERAPEUTICS INC
10955 Vista Sorrento Parkway, Suite 200
San Diego CALIFORNIA US
CEO: David Campbell
Employees: 103
Phone: 13026587581
JANUX THERAPEUTICS INC / JANX FAQ
What does JANX do?
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 109 full-time employees. The company went IPO on 2021-06-11. The company has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
What is the current price of JANX stock?
The current stock price of JANX is 13.84 USD. The price decreased by -0.93% in the last trading session.
What is the dividend status of JANUX THERAPEUTICS INC?
JANX does not pay a dividend.
What is the ChartMill rating of JANUX THERAPEUTICS INC stock?
JANX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is JANUX THERAPEUTICS INC (JANX) stock traded?
JANX stock is listed on the Nasdaq exchange.
What is JANUX THERAPEUTICS INC worth?
JANUX THERAPEUTICS INC (JANX) has a market capitalization of 841.89M USD. This makes JANX a Small Cap stock.
What is the Short Interest ratio of JANUX THERAPEUTICS INC (JANX) stock?
The outstanding short interest for JANUX THERAPEUTICS INC (JANX) is 18.85% of its float.